LSB Industries
LXU
10.20
+0.03
+0.30%
LSB Industries
US · LXU
#3477 by market cap
10.20
+0.03
+0.30%
Live - 5344 symbols - heartbeat 324s ago
· 2026-10-08 07:53
Pre-market
10.35
+1.44%
After-hours
10.20
0.00%
- Market cap
- 734.37M
- P/E (TTM)i
- 20.40
- P/Bi
- 1.36
- EPSi
- 0.34
- Div yieldi
- 0.00%
- 52W posi
- 23%
Reader sentiment
Are you bullish or bearish on LXU?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.83, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +17.77% YoY
Margins
- Gross margin
- 16.95%
- Operating margin
- 9.31%
- Net margin
- 4.00%
Key ratios & quality
- Enterprise valuei
- 1.04B
- Altman Z-Scorei
- 1.83
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 378.16M | 365.07M | 351.32M | 556.24M | 901.71M | 593.71M | 522.40M | 615.21M |
| Gross profit | 15.84M | 4.99M | 17.05M | 138.98M | 348.37M | 86.26M | 47.80M | 104.30M |
| Selling & admin expenses | 40.81M | 34.17M | 32.08M | 38.03M | 39.43M | 36.58M | 41.77M | 41.51M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -23.03M | -39.09M | -15.54M | 101.05M | 308.38M | 51.78M | -5.51M | 57.27M |
| Pretax profit | -70.49M | -84.34M | -66.66M | 38.99M | 269.52M | 33.90M | -26.04M | 32.55M |
| Tax | 1.74M | -20.92M | -4.75M | -4.56M | 39.17M | 5.97M | -6.68M | 7.94M |
| Net profit | -72.23M | -63.42M | -61.91M | 43.55M | 230.35M | 27.92M | -19.35M | 24.61M |
| Basic EPS | -3 | -3 | -3 | -4 | 3 | 0 | 0 | 0 |
| Diluted EPS | -2.88 | -2.65 | -2.71 | -4.40 | 2.68 | 0.37 | -0.27 | 0.34 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 143.43M | 151.30M | 155.43M | 165.05M | 169.49M | 168.09M |
| Gross profit | 14.38M | 23.17M | 25.54M | 41.20M | 35.79M | 11.46M |
| Selling & admin expenses | 10.15M | 9.84M | 10.33M | 11.18M | 13.83M | 12.93M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 4.47M | 10.49M | 15.63M | 26.68M | 23.16M | -2.74M |
| Pretax profit | -1.92M | 4.09M | 9.65M | 20.73M | 17.56M | -8.11M |
| Tax | -283.00K | 1.08M | 2.54M | 4.60M | -2.13M | -1.92M |
| Net profit | -1.64M | 3.01M | 7.12M | 16.13M | 19.69M | -6.19M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.02 | 0.04 | 0.10 | 0.22 | 0.27 | -0.09 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 166.41M | 130.87M | 129.58M | 243.14M | 566.60M | 436.74M | 309.71M | 293.29M |
| Cash & ST investments | 26.05M | 22.79M | 16.26M | 82.14M | 394.32M | 305.93M | 184.20M | 148.47M |
| Inventory | 53.79M | 53.57M | 51.65M | 58.09M | 71.71M | 70.71M | 68.49M | 66.25M |
| Total assets | 1.15B | 1.09B | 1.05B | 1.13B | 1.44B | 1.30B | 1.19B | 1.17B |
| Total current liabilities | 125.81M | 103.30M | 107.30M | 104.93M | 142.31M | 118.53M | 135.63M | 105.51M |
| Short-term debt | 21.10M | 19.34M | 30.38M | 22.17M | 25.66M | 19.25M | 21.26M | 11.45M |
| Long-term debt | 412.68M | 449.63M | 467.39M | 518.19M | 702.73M | 575.87M | 476.16M | 440.30M |
| Total liabilities | 603,967,000.00 | 606,269,000.00 | 631,558,000.00 | 672,350,000.00 | 923,946,000.00 | 779,853,000.00 | 695,548,000.00 | 653,566,000.00 |
| Total equity | 544.37M | 482.22M | 421.74M | 460.49M | 515.87M | 518.33M | 491.64M | 519.97M |
| Retained earnings | 153.77M | 57.63M | -41.49M | -31.26M | 199.09M | 227.02M | 207.66M | 232.28M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 299.33M | 255.21M | 270.62M | 293.29M | 321.30M | 345.57M |
| Cash & ST investments | 163.55M | 124.89M | 151.97M | 148.47M | 181.68M | 217.98M |
| Inventory | 70.24M | 70.48M | 65.11M | 66.25M | 73.11M | 62.62M |
| Total assets | 1.18B | 1.13B | 1.15B | 1.17B | 1.19B | 1.22B |
| Total current liabilities | 119.47M | 96.51M | 95.30M | 105.51M | 104.56M | 142.47M |
| Short-term debt | 15.93M | 10.38M | 2.20M | 11.45M | 7.96M | 4.40M |
| Long-term debt | 478.17M | 446.37M | 447.58M | 440.30M | 440.43M | 440.58M |
| Total liabilities | 685,375,000.00 | 632,283,000.00 | 644,939,000.00 | 653,566,000.00 | 648,408,000.00 | 685,383,000.00 |
| Total equity | 490.56M | 495.80M | 504.61M | 519.97M | 542.95M | 539.22M |
| Retained earnings | 206.02M | 209.03M | 216.14M | 232.28M | 251.96M | 245.77M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 17.62M | 2.10M | -2.51M | 87.63M | 345.65M | 137.52M | 86.58M | 95.52M |
| Depreciation & amortization | 72.63M | 69.57M | 70.84M | 69.94M | 66.94M | 68.92M | 74.48M | 81.93M |
| Free cash flow | -19.43M | -33.98M | -32.98M | 52.50M | 299.82M | 69.92M | -5.72M | 18.06M |
| Dividends paid | -- | 0 | 0 | -1.88M | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 0 | -174.98M | -28.31M | -11.90M | -2.44M |
| Ending cash balance | 26.05M | 22.79M | 16.26M | 82.14M | 63.77M | 101.03M | 20.23M | 19.51M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 6.84M | 18.17M | 52.57M | 17.95M | 51.80M | 59.36M |
| Depreciation & amortization | 20.15M | 20.61M | 19.38M | 21.79M | 20.92M | 21.95M |
| Free cash flow | -14.03M | -315.00K | 35.60M | -3.19M | 34.82M | 19.27M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 3.00K | -2.60M | -- | -- |
| Ending cash balance | 15.03M | 5.61M | 27.95M | 19.51M | 20.64M | 20.36M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -26.53 | -33.05 | -50.86 | -72.47 | 47.18 | 5.40 | -3.83 | 4.87 |
| ROA %i | -8.79 | -8.62 | -9.28 | -20.13 | 17.91 | 2.04 | -1.56 | 2.09 |
| ROIC %i | -8.77 | -8.22 | -7.48 | -21.84 | 23.72 | 5.17 | 0.58 | 4.74 |
| 5-year avg ROE %i | -5.90 | -13.43 | -21.81 | -39.16 | -27.15 | -20.76 | -14.92 | -3.77 |
| EBIT margin %i | -7.25 | -10.40 | -4.42 | 15.89 | 35.08 | 12.64 | 1.61 | 10.27 |
| FCF / sales %i | -- | -- | -- | 9.44 | 33.25 | 11.78 | -- | 2.94 |
| Current ratioi | 1.32 | 1.27 | 1.21 | 2.32 | 3.98 | 3.68 | 2.28 | 2.78 |
| Quick ratioi | 0.74 | 0.61 | 0.55 | 1.61 | 3.30 | 2.92 | 1.64 | 1.95 |
| Debt / assetsi | 37.77 | 44.13 | 49.14 | 49.43 | 51.62 | 47.08 | 43.70 | 41.70 |
| LT debt / equityi | 121.66 | 188.70 | 332.26 | 116.78 | 139.11 | 114.20 | 101.20 | 91.92 |
| Interest coveragei | -0.64 | -0.82 | -0.30 | 1.79 | 6.76 | 1.82 | 0.24 | 2.06 |
| Revenue CAGR (3Y) %i | -4.76 | -0.85 | -6.33 | 13.73 | 35.18 | 19.11 | -2.07 | -11.97 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -52.55 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -60.80 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -5.28 | -6.51 | -0.13 | 4.87 | 8.89 | 7.10 |
| ROA %i | -2.19 | -2.86 | -0.06 | 2.09 | 3.88 | 3.12 |
| ROIC %i | -0.10 | -0.70 | 2.43 | 4.74 | 7.08 | 6.34 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -0.27 | -1.60 | 5.15 | 10.27 | 12.75 | 10.44 |
| FCF / sales %i | -- | -- | -- | 2.94 | 10.43 | 13.14 |
| Current ratioi | 2.51 | 2.64 | 2.84 | 2.78 | 3.07 | 2.43 |
| Quick ratioi | 1.80 | 1.83 | 2.08 | 1.95 | 2.24 | 1.90 |
| Debt / assetsi | 44.20 | 42.82 | 42.31 | 41.70 | 40.64 | 39.32 |
| LT debt / equityi | 102.71 | 95.34 | 95.95 | 91.92 | 87.71 | 88.48 |
| Interest coveragei | -0.04 | -0.27 | 0.96 | 2.06 | 2.75 | 2.38 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Ammonium nitrate (AN) & Nitric Acid is the largest reported line at 41.37% of revenue, across 4 reported segments.
- No single line clears half of revenue; Urea ammonium nitrate (UAN) is next at 37.17%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Ammonium nitrate (AN) & Nitric Acid41.37%
Urea ammonium nitrate (UAN)37.17%
Ammonia15.18%
Other6.28%
Quote time 2026-10-08 07:53:40 · For reference only, not investment advice and not tailored to your situation.